Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Raltegravir vs Efavirenz in Treatment-Naive Patients
- The phase III STARTMRK trial compared raltegravir with efavirenz, both with emtricitabine/tenofovir DF, in 563 treatment-naive patients
- At Week 48, the efficacy of raltegravir was noninferior to that of efavirenz, with 86% and 82%, respectively, achieving HIV-1 RNA < 50 copies/mL by intent-to-treat, noncompleter-equals-failure analysis[Lennox 2009]
- At Week 240, raltegravir was superior to efavirenz with 71% and 61% of patients, respectively, achieving HIV-1 RNA < 50 copies/mL
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy